The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
|Articles|December 2, 2003
- Pharmaceutical Technology-12-02-2003
- Volume 27
- Issue 12
A State of Revision: USP's Guideline for the Submission of Requests for Revision
Author(s)Eric B. Sheinin, PhD
USP's new guideline will assist the industry to help set the monograph standards by which the industry must abide. This column suggests how to apply the guideline to gain maximum benefit.
Advertisement
Articles in this issue
almost 23 years ago
December 2003almost 23 years ago
All Signs Indicate a Strong 2004 for Contract Servicesalmost 23 years ago
Behavior of Uptake of Moisture by Drugs and Excipientsalmost 23 years ago
Targeted Cationic Liposomes, Technologies, and Developmentsalmost 23 years ago
Sixth Annual International Employment Survey: Staying the Coursealmost 23 years ago
Drug Pricing Concerns Shape Policy Decisions in 2003almost 23 years ago
In the Spotlight--January 2004almost 23 years ago
December 2003Advertisement
Related to this article
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
3
Can AI Agents Satisfy CGMP Documentation Requirements?
4
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
5